2022/08/17
MIDDLETOWN, Delaware, August 16, 2022 鈥 WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware. First announced in June 2021, this site will be WuXi STA鈥檚 second facility in the United States, offering expanded capacity and greater flexibility to meet the needs of customers in the U.S. and around the world.
Read more2022/08/12
August 11, 2022 鈥 PHILADELPHIA, PA. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi ATU will license to Janssen its TESSA? technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems. Janssen will also have access to work on WuXi ATU鈥檚 proprietary clonal suspension HEK293 cell line. This agreement was facilitated by Johnson & Johnson Innovation.
Read more2022/07/26
(SHANGHAI, July 26, 2022) 鈥 WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first half of the year ending June 30, 2022 (鈥淩eporting Period鈥).
Read more
2022/08/17
MIDDLETOWN, Delaware, August 16, 2022 鈥 WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware. First announced in June 2021, this site will be WuXi STA鈥檚 second facility in the United States, offering expanded capacity and greater flexibility to meet the needs of customers in the U.S. and around the world.
Read more2022/08/12
August 11, 2022 鈥 PHILADELPHIA, PA. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi ATU will license to Janssen its TESSA? technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems. Janssen will also have access to work on WuXi ATU鈥檚 proprietary clonal suspension HEK293 cell line. This agreement was facilitated by Johnson & Johnson Innovation.
Read more2022/07/26
(SHANGHAI, July 26, 2022) 鈥 WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first half of the year ending June 30, 2022 (鈥淩eporting Period鈥).
Read more2022/07/19
SINGAPORE, July 19, 2022 鈥 WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site in Singapore. The company intends to invest up to S$2 billion (approximately US$1.43 billion) to construct and operationalize the site, which aims to further enable global partners to advance healthcare innovations. The investment is expected to be made in stages over the next 10 years, depending on the company鈥檚 business needs.
Read more2022/07/07
Shanghai, China, July 6, 2022 - WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus. The new facility underscores WuXi STA鈥檚 ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide, making more innovative therapies accessible to the patients.
Read more2022/08/17
MIDDLETOWN, Delaware, August 16, 2022 鈥 WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware. First announced in June 2021, this site will be WuXi STA鈥檚 second facility in the United States, offering expanded capacity and greater flexibility to meet the needs of customers in the U.S. and around the world.
Read more2022/08/12
August 11, 2022 鈥 PHILADELPHIA, PA. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi ATU will license to Janssen its TESSA? technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems. Janssen will also have access to work on WuXi ATU鈥檚 proprietary clonal suspension HEK293 cell line. This agreement was facilitated by Johnson & Johnson Innovation.
Read more2022/07/26
(SHANGHAI, July 26, 2022) 鈥 WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first half of the year ending June 30, 2022 (鈥淩eporting Period鈥).
Read more2022/07/19
SINGAPORE, July 19, 2022 鈥 WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site in Singapore. The company intends to invest up to S$2 billion (approximately US$1.43 billion) to construct and operationalize the site, which aims to further enable global partners to advance healthcare innovations. The investment is expected to be made in stages over the next 10 years, depending on the company鈥檚 business needs.
Read more2022/07/07
Shanghai, China, July 6, 2022 - WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus. The new facility underscores WuXi STA鈥檚 ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide, making more innovative therapies accessible to the patients.
Read more